Human organoids: Fit for drug discovery?

Organoids are self-organizing three-dimensional (3D) in vitro tissues derived from pluripotent stem cells (PSCs) that recapitulate key structural and functional features of human organs. Their multicellular architecture and physiological relevance make them promising new approach methodologies (NAMs) for disease modeling, drug discovery, and toxicity testing. However, their reliability and scalability for compound screening remain under evaluation. This review summarizes current human PSC-derived organoid screening strategies, highlighting available readouts, related machine learning methods, and their potential advantages over traditional screening models. We also discuss major challenges, including assay robustness, throughput limitations, and the need for standardized protocols. Advancing validated and scalable approaches will be essential for integrating organoids into pharmaceutical development and improving the translational success of drug candidates.

Authors

Institutions

Publication Details

Journal
Stem Cell Reports
Published
2026-05-01
DOI
https://doi.org/10.1016/j.stemcr.2026.102898
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Human organoids: Fit for drug discovery?

Alessandro Prigione, Annika Wittich, Kim Krieg, Philip Gribbon et al.
Stem Cell Reports
Cancer Cells and Metastasis
article

Human organoids: Fit for drug discovery?

Alessandro Prigione, Annika Wittich, Kim Krieg, Philip Gribbon, Ole Pless, Jakob J. Metzger
article en

Abstract

Organoids are self-organizing three-dimensional (3D) in vitro tissues derived from pluripotent stem cells (PSCs) that recapitulate key structural and functional features of human organs. Their multicellular architecture and physiological relevance make them promising new approach methodologies (NAMs) for disease modeling, drug discovery, and toxicity testing. However, their reliability and scalability for compound screening remain under evaluation. This review summarizes current human PSC-derived organoid screening strategies, highlighting available readouts, related machine learning methods, and their potential advantages over traditional screening models. We also discuss major challenges, including assay robustness, throughput limitations, and the need for standardized protocols. Advancing validated and scalable approaches will be essential for integrating organoids into pharmaceutical development and improving the translational success of drug candidates.

Stem Cell Reports
Max Delbrück Center (DE), Düsseldorf University Hospital (DE), Fraunhofer Institute for Translational Medicine and Pharmacology (DE), Heinrich Heine University Düsseldorf (DE)
French Muscular Dystrophy Association, Deutsche Forschungsgemeinschaft, Deutsches Zentrum für Luft- und Raumfahrt, HORIZON EUROPE Framework Programme
Zero hunger
Openalex Percentile: Top 8%
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.